Sentiment for Ani Pharmaceuticals Inc (NASDAQ:ANIP)
Ani Pharmaceuticals Inc (NASDAQ:ANIP) institutional sentiment increased to 1.96 in Q2 2019. Its up 0.16, from 1.8 in 2019Q1. The ratio has increased, as 96 active investment managers started new or increased positions, while 49 sold and decreased their stakes in Ani Pharmaceuticals Inc. The active investment managers in our partner’s database now possess: 8.26 million shares, up from 7.50 million shares in 2019Q1. Also, the number of active investment managers holding Ani Pharmaceuticals Inc in their top 10 positions was flat from 1 to 1 for the same number . Sold All: 8 Reduced: 41 Increased: 67 New Position: 29.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $726.91 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It has a 44.97 P/E ratio. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.
The stock increased 0.99% or $0.59 during the last trading session, reaching $60.12. About 93,671 shares traded. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has risen 25.49% since December 4, 2018 and is uptrending. It has outperformed by 25.49% the S&P500.
Analysts await ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to report earnings on February, 26. They expect $1.02 EPS, down 15.00 % or $0.18 from last year’s $1.2 per share. ANIP’s profit will be $12.33 million for 14.74 P/E if the $1.02 EPS becomes a reality. After $1.07 actual EPS reported by ANI Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -4.67 % negative EPS growth.
Mangrove Partners holds 5.11% of its portfolio in ANI Pharmaceuticals, Inc. for 549,401 shares. 1492 Capital Management Llc owns 25,181 shares or 1.94% of their US portfolio. Moreover, Hawk Ridge Capital Management Lp has 1.88% invested in the company for 123,561 shares. The Minnesota-based Perkins Capital Management Inc has invested 1.72% in the stock. Thb Asset Management, a Connecticut-based fund reported 89,305 shares.
Since January 1, 0001, it had 0 insider purchases, and 2 insider sales for $4.94 million activity.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Ratings Coverage
Ratings analysis reveals 100% of ANI Pharmaceuticals’s analysts are positive. Out of 2 Wall Street analysts rating ANI Pharmaceuticals, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $7500 while the high is $7600. The stock’s average target of $75.50 is 25.58% above today’s ($60.12) share price. ANIP was included in 4 notes of analysts from September 12, 2019. The rating was maintained by Raymond James with “Outperform” on Thursday, November 7.
More notable recent ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) news were published by: Prnewswire.com which released: “ANI Announces Positive Clinical Results from Cortrophin® Gel Cortisol Response Study – PRNewswire” on October 03, 2019, also Finance.Yahoo.com with their article: “Does ANI Pharmaceuticals (NASDAQ:ANIP) Deserve A Spot On Your Watchlist? – Yahoo Finance” published on October 12, 2019, Seekingalpha.com published: “New coverage – healthcare – Seeking Alpha” on September 12, 2019. More interesting news about ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) were released by: Streetinsider.com and their article: “Form 8-K ANI PHARMACEUTICALS INC For: Nov 26 – StreetInsider.com” published on November 26, 2019 as well as Finance.Yahoo.com‘s news article titled: “How Much is ANI Pharmaceuticals, Inc.’s (NASDAQ:ANIP) CEO Getting Paid? – Yahoo Finance” with publication date: July 09, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.